Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolor Biotech has reported positive results of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) from a comparative study in hemophilic mice.
Subscribe to our email newsletter
Factor VIIa is used to treat hemophilia A and B patients who have developed inhibitors against treatment with either Factor VIII or IX and are suferring from acute bleeding episodes.
The study was designed to measure clotting activity and the potential increase in half-life of the new long acting drug with the commercially available recombinant Factor VIIa.
The results from the preclinical study evaluated that the new long acting drug has longer half-life and duration of clotting activity in the hemophilic mice model compared with available Factor VIIa.
Prolor president Shai Novik said with the positive results from this Factor VIIa-CTP study, they now have what they believe are two competitive coagulation therapies in development that address a target market estimated at approximately $2bn.